Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SunPine AB and its shareholders
Mandate

Vinge advises SunPine AB and its shareholders

December 06, 2012

Vinge has advised SunPine AB, a company conducting operations in the biodiesel industry and the company’s shareholders (Sveaskog Förvaltnings Aktiebolag (publ), Södra Skogsägarana co-operative association, Preem Aktiebolag (publ) and Kiram AB) in a joint venture with Lawter BVBA (a subsidiary of Harima Chemical Group Inc.) regarding the construction of a resin plant at SunPine’s facility in Piteå.

Vinge’s team consisted of, among others, partners Malin Ohlin and Christina Kokko and associates Christian Hybbinette, Claes Henriksson, Jonatan Lund Kirkhoff and Mårten Svensson. 

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026